STAT+: Maryland State Affordability Board Sets Its First Price Cap for a Medicine

Why It Matters

State‑level caps introduce a new lever to control soaring prescription costs and could pressure manufacturers to reconsider pricing nationwide. Maryland’s move signals growing political appetite for systematic drug‑price regulation.

Key Takeaways

• Maryland caps Jardiance at $204 for 30‑day supply by 2027.
• Expected annual savings of $320,000 for state and local budgets.
• Cap based on Medicare fair price, adjusted for inflation.
• Only second U.S. state to impose a diabetes drug price ceiling.

Pulse Analysis

The Maryland Prescription Drug Affordability Board, created in 2022, operates like a utility commission, reviewing drug costs for state‑run health programs. Its mandate reflects mounting pressure on policymakers to address the relentless rise in specialty medication prices that strain public budgets and patient access. By establishing a formal pricing framework, Maryland joins a small but growing cohort of states experimenting with direct price controls, a strategy that could reshape the traditional negotiation dynamics between insurers and manufacturers.

Jardiance, an SGLT2 inhibitor widely prescribed for type‑2 diabetes, has become a cost driver for many health plans. The board’s decision to cap the drug at $204 for a 30‑day supply—about $6.80 per tablet—leans on the Medicare maximum fair price, with an inflation adjustment to reflect projected 2027 costs. This ceiling translates into roughly $320,000 in annual savings for Maryland’s state and local entities, a modest but symbolically powerful figure that demonstrates the board’s capacity to generate tangible fiscal relief without compromising clinical efficacy.

The broader implications extend beyond Maryland’s borders. As the second state to enact a diabetes drug price ceiling, Maryland sets a precedent that could embolden other jurisdictions to adopt similar mechanisms, potentially prompting pharmaceutical firms to pre‑emptively adjust pricing strategies. While manufacturers may argue that caps could hinder innovation funding, policymakers argue that affordable access is a public health imperative. If more states follow suit, the cumulative effect could pressure federal agencies to revisit Medicare pricing benchmarks, ushering in a new era of coordinated, market‑based drug cost containment.